Tofacitinib and faecal microbiota transplantation in treating checkpoint inhibitor-induced enterocolitis: case report

BACKGROUND: Immune checkpoint inhibitors (ICIs) can induce a wide range of immune-related adverse events (irAEs), potentially affecting any organ. ICI-induced colitis is a frequently reported irAE, whereas enteritis is rare and not well documented. CASE PRESENTATION: We are presenting a patient with...

Descripción completa

Detalles Bibliográficos
Autores principales: Holmstroem, Rikke Boedker, Dahl, Emilie Kristine, Helms, Morten, Nielsen, Henrik Vedel, Andersen, Janne Bayer, Bjerrum, Jacob Tveiten, Svane, Inge Marie, Ellebaek, Eva, Seidelin, Jakob Benedict
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Inflammatory Bowel Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806036/
https://www.ncbi.nlm.nih.gov/pubmed/36581371
http://dx.doi.org/10.1136/bmjgast-2022-000989
Descripción
Sumario:BACKGROUND: Immune checkpoint inhibitors (ICIs) can induce a wide range of immune-related adverse events (irAEs), potentially affecting any organ. ICI-induced colitis is a frequently reported irAE, whereas enteritis is rare and not well documented. CASE PRESENTATION: We are presenting a patient with metastatic melanoma who developed severe ICI-induced enterocolitis multirefractory for glucocorticoids, infliximab and vedolizumab, partially responding to faecal microbiota transplantation and final complete response to tofacitinib. CONCLUSION: This case supports that tofacitinib may be an(other) effective agent in managing multirefractory ICI-induced diarrhoea caused by colitis and/or enteritis.

Ejemplares similares